Targeted approaches to bypass defects in IFN signalling and antigen presentation or to inhibit immunosuppressive oncogenic signalling pathways hold promise in broadening the impact of immune checkpoint blockade
Targeted approaches to bypass defects in IFN signalling and antigen presentation or to inhibit immunosuppressive oncogenic signalling pathways hold promise in broadening the impact of immune checkpoint blockade. Acknowledgements The authors are supported by grants from the Parker Institute for Cancer Immunotherapy (A.R.), the US National Institutes of Health (grant R35 CA197633 to A.R.), the…